Virbac SA (VRBCF)
USD 324.0
(0.0%)
USD 324.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 121.26 Million EUR | 34.15% |
| 2022 | 90.39 Million EUR | -4.31% |
| 2021 | 94.46 Million EUR | -18.14% |
| 2020 | 115.39 Million EUR | -74.87% |
| 2019 | 459.25 Million EUR | -5.64% |
| 2018 | 486.71 Million EUR | -3.86% |
| 2017 | 506.27 Million EUR | -14.29% |
| 2016 | 590.7 Million EUR | -9.67% |
| 2015 | 653.95 Million EUR | 14.68% |
| 2014 | 570.24 Million EUR | 165.05% |
| 2013 | 215.14 Million EUR | 25.35% |
| 2012 | 171.64 Million EUR | 87.01% |
| 2011 | 91.78 Million EUR | 112.86% |
| 2010 | 43.11 Million EUR | -10.0% |
| 2009 | 47.9 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 80.34 Million EUR | 179.5% |
| 2005 | 28.74 Million EUR | -44.9% |
| 2004 | 52.16 Million EUR | -14.15% |
| 2003 | 60.76 Million EUR | 28.9% |
| 2002 | 47.14 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 369.95 Million EUR | 205.07% |
| 2024 Q2 | 369.95 Million EUR | 10.01% |
| 2023 Q1 | 159.21 Million EUR | 76.13% |
| 2023 Q4 | 121.26 Million EUR | 8.12% |
| 2023 Q3 | 112.16 Million EUR | -32.36% |
| 2023 Q2 | 165.82 Million EUR | 4.15% |
| 2023 FY | 121.26 Million EUR | 34.15% |
| 2022 Q4 | 90.39 Million EUR | 3.37% |
| 2022 Q1 | 145.95 Million EUR | 54.5% |
| 2022 FY | 90.39 Million EUR | -4.31% |
| 2022 Q2 | 148.38 Million EUR | 1.66% |
| 2022 Q3 | 87.44 Million EUR | -41.07% |
| 2021 FY | 94.46 Million EUR | -18.14% |
| 2021 Q1 | 120.59 Million EUR | 4.51% |
| 2021 Q3 | 89.02 Million EUR | -29.95% |
| 2021 Q4 | 94.46 Million EUR | 6.11% |
| 2021 Q2 | 127.08 Million EUR | 5.38% |
| 2020 FY | 115.39 Million EUR | -74.87% |
| 2020 Q2 | 462.17 Million EUR | 0.98% |
| 2020 Q4 | 115.39 Million EUR | 5.23% |
| 2020 Q1 | 457.67 Million EUR | -0.34% |
| 2020 Q3 | 109.66 Million EUR | -76.27% |
| 2019 Q4 | 459.25 Million EUR | 1.41% |
| 2019 Q2 | 523.71 Million EUR | 1.22% |
| 2019 Q3 | 452.85 Million EUR | -13.53% |
| 2019 Q1 | 517.38 Million EUR | 6.3% |
| 2019 FY | 459.25 Million EUR | -5.64% |
| 2018 Q3 | 487.19 Million EUR | -9.96% |
| 2018 Q1 | 540.82 Million EUR | 6.82% |
| 2018 FY | 486.71 Million EUR | -3.86% |
| 2018 Q4 | 486.71 Million EUR | -0.1% |
| 2018 Q2 | 541.08 Million EUR | 0.05% |
| 2017 Q4 | 506.27 Million EUR | 0.13% |
| 2017 FY | 506.27 Million EUR | -14.29% |
| 2017 Q2 | 587.7 Million EUR | 0.23% |
| 2017 Q1 | 586.33 Million EUR | -0.74% |
| 2017 Q3 | 505.63 Million EUR | -13.96% |
| 2016 Q1 | 663.79 Million EUR | 1.5% |
| 2016 FY | 590.7 Million EUR | -9.67% |
| 2016 Q4 | 590.7 Million EUR | 0.14% |
| 2016 Q3 | 589.88 Million EUR | -10.6% |
| 2016 Q2 | 659.82 Million EUR | -0.6% |
| 2015 FY | 653.95 Million EUR | 14.68% |
| 2015 Q4 | 653.95 Million EUR | 0.05% |
| 2015 Q1 | 679.73 Million EUR | 19.2% |
| 2015 Q3 | 653.61 Million EUR | -3.13% |
| 2015 Q2 | 674.72 Million EUR | -0.74% |
| 2014 Q3 | 572.18 Million EUR | 86.61% |
| 2014 Q1 | 305.36 Million EUR | 41.94% |
| 2014 FY | 570.24 Million EUR | 165.05% |
| 2014 Q4 | 570.24 Million EUR | -0.34% |
| 2014 Q2 | 306.62 Million EUR | 0.41% |
| 2013 FY | 215.14 Million EUR | 25.35% |
| 2013 Q4 | 215.14 Million EUR | 0.82% |
| 2013 Q3 | 213.4 Million EUR | -13.47% |
| 2013 Q2 | 246.6 Million EUR | 0.28% |
| 2013 Q1 | 245.93 Million EUR | 43.28% |
| 2012 FY | 171.64 Million EUR | 87.01% |
| 2012 Q4 | 171.64 Million EUR | 0.0% |
| 2012 Q2 | 11.77 Million EUR | 0.0% |
| 2011 Q2 | 30.31 Million EUR | 0.0% |
| 2011 Q4 | 91.78 Million EUR | 0.0% |
| 2011 FY | 91.78 Million EUR | 112.86% |
| 2010 FY | 43.11 Million EUR | -10.0% |
| 2010 Q2 | 58.47 Million EUR | 0.0% |
| 2010 Q4 | 43.11 Million EUR | 0.0% |
| 2009 Q4 | 47.9 Million EUR | 0.0% |
| 2009 FY | 47.9 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 80.34 Million EUR | 179.5% |
| 2005 FY | 28.74 Million EUR | -44.9% |
| 2004 FY | 52.16 Million EUR | -14.15% |
| 2003 FY | 60.76 Million EUR | 28.9% |
| 2002 FY | 47.14 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 99.576% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.708% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -21.698% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -186.893% |
| Novartis AG | 26.34 Billion USD | 99.54% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -200.123% |